DKB 20002
Alternative Names: DKB-20002Latest Information Update: 21 Dec 2021
At a glance
- Originator DongKoo Bio&Pharma
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Diabetes mellitus
Most Recent Events
- 15 Dec 2021 Preclinical trials in Diabetes mellitus in South Korea (unspecified route) as of December 2021 (DongKoo Bio&Pharma pipeline; December 2021)